{
  "docId": "019de071-f36b-702d-acba-b009d415a6aa",
  "docSlug": "7f10ea97b4031d406788e9f98a2cb8e4",
  "documentTitle": "Alkermes | Investor Conference Presentation Deck | 36 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 36,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a human body diagram to map tumor types treated with monotherapy vs. combination therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f36b-702d-acba-b009d415a6aa/27",
  "deckHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa",
  "deckJsonHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa.json",
  "deckAnchorHref": "/decks/019de071-f36b-702d-acba-b009d415a6aa#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "disclaimer",
      "text": "IV: Intravenous; SC: Subcutaneous. Includes one response from ARTISTRY-2... Data as of May 3, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2b2429c-02ef-4615-bdea-04b779ea9643",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "image",
      "text": "Human body diagram showing tumor types treated",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9da1b5bc-b5f6-4a9f-9b9e-80e9d179c539",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "list",
      "text": "Designed to avoid hallmark toxicities of high-dose IL-2; Treatment-related adverse events (AEs) in ARTISTRY-1 and ARTISTRY-2 have been consistent with expectations and were mostly transient and manageable",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49087ed0-ad21-4d47-a0ee-a1fc7a2fa186",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "Demonstrated durable and deepening responses in high unmet need populations; Monotherapy activity in prior anti-PD-(L)1 treated melanoma and renal cell carcinoma; Combination activity with pembrolizumab in a range of tumor types",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d738863-5a79-4353-9873-98ba9e087807",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Nemvaleukin: Durable and Deepening Responses Observed",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66651c95-9931-44b7-aa86-8fc797db9d8e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a3f559d9-253a-419e-8135-aa99c1d8f794",
      "evidence": "list/bullet: Demonstrated durable and deepening responses in high unmet need populations; Monotherapy activity in prior anti-PD-(L)1 treated melanoma and renal cell carcinoma; Combination activity with pembrolizumab in a",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 34,
      "from": 23,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4e1affb3-fc2c-436d-a5c0-492bd8d09819",
      "evidence": "The deck presents an overview of the innovation pipeline and its potential benefits",
      "position": 0,
      "objective": "Highlighting the importance of Alkermes' innovation pipeline",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}